Biomarin Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.11.22	BioMarin: FDA No Longer Plans To Hold Advisory Committee Meeting To Discuss BLA (RTTNews)
23.11.22	BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A (PR Newswire)
07.11.22	BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program (PR Newswire)
03.11.22	BioMarin to Participate in Two Upcoming Investor Conferences (PR Newswire)
01.11.22	Form 4 1048477 (RSS)
28.10.22	Form 10-Q 1048477 (RSS)
27.10.22	BMRN Faces FDA In March, ALGN's Q3 Results Disappoint, VKTX Awaits VOYAGE… (RTTNews)
26.10.22	Biomarin Pharmaceutical Inc. Q3 Loss decreases, but misses estimates (RTTNews)
26.10.22	BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®) (PR Newswire)
26.10.22	Form 8-K 1048477 (RSS)
12.10.22	FDA Accepts BioMarin's BLA For Hemophilia A Gene Therapy (RTTNews)
12.10.22	FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A (PR Newswire)
07.10.22	Current report (RSS)
07.10.22	BioMarin Reduces About 4% Of Global Workforce (RTTNews)
07.10.22	BioMarin Simplifies Organizational Structure to Increase Efficiency (PR Newswire)
04.10.22	BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET (PR Newswire)
29.09.22	BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA (PR Newswire)
15.09.22	BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report (PR Newswire)
24.08.22	European Commission Grants BioMarin's Roctavian CMA For Treatment Of Hemophilia A In Adult Patients (RTTNews)
24.08.22	First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) (PR Newswire)
03.08.22	Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2, Beats estimates (RTTNews)
03.08.22	BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance (PR Newswire)
20.07.22	BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET (PR Newswire)
11.07.22	BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Incl... (PR Newswire)
24.06.22	Positive CHMP Opinion For BioMarin's Gene Therapy To Treat Severe Hemophilia A (RTTNews)
24.06.22	BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A (PR Newswire)
21.06.22	BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growt... (PR Newswire)
13.06.22	BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, END... (PR Newswire)
31.05.22	BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A (PR Newswire)
26.05.22	Statement of changes in beneficial ownership of securities (RSS)
11.05.22	Initial statement of beneficial ownership of securities (RSS)
05.05.22	BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans (PR Newswire)
05.05.22	BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including ... (PR Newswire)
05.05.22	Form 8-K 1048477 (RSS)
04.05.22	BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET (PR Newswire)
02.05.22	Form 4 1048477 (RSS)
27.04.22	Biomarin Pharmaceutical Inc. Announces Climb In Q1 Income, Beats estimates (RTTNews)
27.04.22	BioMarin Announces Record Revenues in First Quarter 2022 (PR Newswire)
20.04.22	Form 4 1048477 (RSS)
13.04.22	BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET (PR Newswire)
12.04.22	Form DEF 14A 1048477 (RSS)
12.04.22	Form DEFA14A 1048477 (RSS)
23.03.22	Form 4 1048477 (RSS)
17.03.22	BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A (PR Newswire)
17.03.22	Statement of changes in beneficial ownership of securities (RSS)
10.03.22	Form 4 1048477 (RSS)
02.03.22	Form 4 1048477 (RSS)
25.02.22	Form 10-K 1048477 (RSS)
23.02.22	Biomarin Pharmaceutical Inc. Q4 Earnings Summary (RTTNews)
23.02.22	BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

16.09.24

NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus

16.09.24

NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag

16.09.24

Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer

16.09.24

Verluste in New York: NASDAQ Composite verliert zum Start

06.08.24

Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus

06.08.24

Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich